Tying these polygenic score cost effectiveness studies in here as most have been published since the ICDA PRS Task Force paper. As one would expect from a one-time sub-£100 assay that can be applied to dozens of clinical pathways, PGS cost effectiveness i
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
Glad to see more research answering this question!
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
RT @minouye271: Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/q…
Studies assessing cost-effectiveness of polygenic scores in screening Breast cancer: https://t.co/M0Ospc4Xkh https://t.co/qx7go5ZtQ2 CRC: https://t.co/6i3OdGV3BL CVD: https://t.co/I2dmNhN1pb https://t.co/IIhOeyY8a9 T2D: https://t.co/rw2KX7SjRY
#ICYMI: The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis by Chloe Thomas, @JulietU_S, and colleagues @ScHARRSheffield. https://t.co/3jCtBmejdQ https://t.co/fcGwGL
The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis. https://t.co/Hcg1tHFdyp #AACRcrc21 https://t.co/iOlSI9LOvX
#ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis. https://t.co/51cEeErbYK @ScHARRSheffield @JulietU_S https://t.co/UHmpuEOis5
RT @ScHARRHUD: ScHARRSheffield: RT @CAPR_AACR: #ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based…
ScHARRSheffield: RT @CAPR_AACR: #ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis. https://t.co/o9H52jjnjx @ScHARRSheffield @JulietU_S https://t.co/DpTo1cV
RT @CAPR_AACR: #ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk:…
ScHARRSheffield: RT @CAPR_AACR: #ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis. https://t.co/BLdIxeTGB7 @ScHARRSheffield @JulietU_S https://t.co/IbWLaTH
RT @CAPR_AACR: #ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk:…
RT @CAPR_AACR: #ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk:…
#ICYMI— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis. https://t.co/OZyfAGy6UV @ScHARRSheffield @JulietU_S https://t.co/tJLKMOOqV6
From the August issue— The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis. https://t.co/wJ1hFhEEma @ScHARRSheffield @JulietU_S https://t.co/QrrTVDcshQ
RT @ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic…
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/Y1dx01Vyby ht
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/4kv0WtbIAI ht
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/MSDRJvdQaC ht
New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/zo5eoJ8gSX https://t.co/V
RT @ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic…
RT @ScHARRmscihta: ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based…
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/Y1dx01Vyby ht
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/4kv0WtbIAI ht
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/MSDRJvdQaC ht
New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/zo5eoJ8gSX https://t.co/M
Well done Chloe Thomas et al! #ColorectalCancer #Research #HealthEconomicsAnalysis #HEOR
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/Y1dx01Vyby ht
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/4kv0WtbIAI ht
ScHARRHEDS: New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/MSDRJvdQaC ht
New research publication The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/zo5eoJ8gSX https://t.co/T
RT @ScHARRHEDS: New research publication 'The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic…
New research publication 'The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis' led by Chloe Thomas @ScHARRHEDS @ScHARRSheffield https://t.co/wIfmIn1nKM https://t.c
RT @minouye271: The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a healt…
RT @minouye271: The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a healt…
RT @minouye271: The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a healt…
The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis https://t.co/0GEW1K8qjG https://t.co/544q287TDZ
Risk-stratified screening for bowel cancer has potential to be a fairly resource-neutral means of improving the effectiveness of the screening programme. @JulietU_S @ScHARRHEDS @PCU_Prevention @DrCLSaunders @bowelcanceruk https://t.co/a9WhA1eNOy
The #costs and #benefits of risk-stratification for #colorectal #cancer screening based on phenotypic and genetic risk: a health economic analysis https://t.co/HudzoCVQ1a
ScHARRHEDS: RT @DrCLSaunders: Working with @JulietU_S in @PCU_Cambridge over the last few years has been a really fab part of my job. Apart from the whole "thinking about how to model SNPs for the first time since my PhD nearly 20 years ago" https://t.co/
ScHARRHEDS: RT @DrCLSaunders: Working with @JulietU_S in @PCU_Cambridge over the last few years has been a really fab part of my job. Apart from the whole "thinking about how to model SNPs for the first time since my PhD nearly 20 years ago" https://t.co/
ScHARRHEDS: RT @DrCLSaunders: Working with @JulietU_S in @PCU_Cambridge over the last few years has been a really fab part of my job. Apart from the whole "thinking about how to model SNPs for the first time since my PhD nearly 20 years ago" https://t.co/
New article: The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis https://t.co/JSe9nwAeK7 #colorectalcancer #oncology https://t.co/OxUTtMzXAa